Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Summary

The main purpose of this study is to evaluate the safety and immunogenicity of three dosage levels (low, medium, high) of the bivalent combination respiratory syncytial virus (RSV)/human metapneumovirus (hMPV) virus-like particle (VLP) candidate vaccine (IVX-A12), compared to placebo, when administered as a single-dose regimen in healthy older adults 60 to 75 years of age.

Timeline

Start

2022-09-21

Primary completion

2024-01-24

Completion

2024-01-24

Drugs

Indications

No indication recorded.